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     Abstract:  
 
Background: Several clinical trials have tested the safety profile of sodium-glucose co-transport inhibitors’ 
(SGLTis) in adult type 1 diabetes mellitus (T1DM) patients. However, no systematic review has yet compared its 
variation between large and low dose SGLTis. Henceforth, a review protocol is proposed here to review it. 
Methods: Different electronic databases will be searched for randomized-controlled trials (published in the English 
language) studying the above objective, irrespective of their publication date. After selecting the eligible trials, their 
data on the study design, population characteristics, compared interventions, and outcomes of interest will be 
extracted. Then, utilizing the Cochrane tool, each trial's risk of selection bias, detection bias, performance bias, 
attrition bias, reporting bias, and other bias will be judged. Next, depending on clinical heterogeneity among the 
trials, a random-effect or fixed-effect model meta-analysis will be used to compare the respective outcomes. Via 
the Chi2 and I2 statistics, the statistical inconsistency among the trials will be estimated. When this is substantial, 
subgroup analysis will follow. Publication bias will be evaluated by funnel plots and Egger’s test. A sensitivity 
analysis will be done to check different assumptions. If a quantitative juxtaposition is not possible, a narrative 
reporting will ensue. 
Conclusion: The proposed study will perform a dose-wise juxtaposition of the safety profile of SGLTis in insulin-
treated T1DM patients.  
Registration: Prospective Register of Systematic Reviews (PROSPERO) (Registration no. CRD42019146578) 
Keywords: Type 1 Diabetes, Sodium-Glucose Transporter 1, Sodium-Glucose Transporter 2, Drug-Related Side 
Effects and Adverse Reactions, Randomized Controlled Trial 
 
Background  
The autoimmune destruction of insulin (an anabolic hormone) 
producing pancreatic beta-cells leads to type 1 diabetes mellitus 
(T1DM), a disease characterized by hyperglycemia [1,2]. 
Although the exact etiology of the disease is unknown, the 
genetic predisposition may have some role. Individuals with 
certain human leukocyte antigen alleles (DR and DQ) are at 
greater risk of developing T1DM upon exposure to various 
trigger agents like viruses, environmental toxins, and dietary 
factors [1]. T1DM frequently begins between 4-6 and 10-14-
year-olds, although it can start at any age [1]. About 5-10% of 
diabetes patients are T1DM patients [1]. Complications of 
T1DM often include neuropathy, nephropathy, retinopathy, 
hypoglycemia, diabetic ketoacidosis, cardiomyopathy, and 
diabetic foot disease [1]. To prevent these hyperglycemic 
complications in T1DM patients, insulin, the mainstay of 
treatment, is required lifelong [1–3].  
     However, this entire insulin dependence doesn't suit every 
T1DM patient, because of the inconveniences of insulin therapy 
like multiple daily insulin injections and daily finger pricks to 
control and self-monitor the blood glucose levels, 
respectively.[4,5] Besides, there are adverse consequences of 
intensive insulin therapy on the health like lipohypertrophy or 
atrophy (when insulin is repeatedly injected at the same site), 
unwanted weight gain, raised risk of hypoglycemic episodes, 
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absolute insulin therapy might affect the health and treatment of 
T1DM patients further. For instance, the subsequent injections 
in insulin-induced lipohypertrophied areas can slow down 
insulin absorption [6]. Likewise, the insulin-induced weight 
gain might raise the risk of cardiometabolic complications by 
decreasing compliance with the insulin regimen [6]. Therefore, 
to reduce the discomforts and complications of intensive insulin 
therapy, the role of insulin-independent adjunct therapeutics is 
vital in the treatment of T1DM patients. In this regard, sodium-
glucose co-transport inhibitors (SGLTis) have drawn significant 
attention of the medical community.  
     SGLTis are phlorizin compounds [2,4]. By inhibiting 
sodium-glucose transporter 1 (SGLT1) and sodium-glucose 
transporter 2 (SGLT2) receptors, SGLTis cause glycosuria and 
decreased intestinal absorption of glucose [4]. SGLT2 receptors 
in the proximal convoluted tubule reabsorb almost 90% of the 
filtered glucose [6–8]. Examples of SGLT2 inhibitors include 
dapagliflozin, empagliflozin, and canagliflozin [9]. SGLT1 is 
predominantly found in the intestine, and its inhibition regulates 
the blood glucose level by increasing the release of 
gastrointestinal hormones through increased glucose delivery to 
the distal small intestine [6]. Sotagliflozin is a dual SGLT2/1 
blocker; its capacity to inhibit SGLT1 receptors provides an 
additional benefit in decreasing the glucose levels 
postprandially [2].  
     Existing early stage trials suggested several efficacies of 
SGLTis in T1DM patients. Such trials comparing SGLT2 
inhibitors (dapagliflozin: 5 mg and 10 mg, empagliflozin: 25 
mg, 10 mg, and 2.5 mg, and canagliflozin: 100 mg and 300 mg) 
to placebo in insulin-treated inadequately controlled T1DM 
patients,  demonstrated an improvement in glycemic control, 
body weight, and insulin requirement [10–12]. Likewise, trials 
that investigated sotagliflozin in T1DM patients and type 2 
diabetes mellitus (T2DM) patients, observed improvement in 
glycemic control (by limiting the post-meal glycemic 
excursions), weight control, and daily insulin requirements [13]. 
A recent meta-analysis suggested that mega-dose empagliflozin 
treatment in insulin-treated T1DM patients with optimum renal 
functioning aids in achieving better glycemic control, compared 
to the placebo [14]. 
     However, despite these benefits, due to safety concerns, both 
sotagliflozin [15] and SGLT2 inhibitors are currently not 
approved by the U.S. Food and Drug Administration [16]. 
Therefore, it is crucial to research the safety of SGLTis 
extensively. Contemporarily, several randomized controlled 
clinical trials have reported the safety profile of SGLTis in 
T1DM patients [12,17–19]. Although a statistical comparison of 
these side effects between the treatment arms was not available, 
based on its frequency, some idea about the safety profile of 
SGLTis can be made. The trials [12,17,18] on T1DM patients 
that compared the safety profile between large and low dose 
empagliflozin, canagliflozin, dapagliflozin observed that the 
overall percentage of side-effects due to any cause were higher 
in the recipients of the former. In these large dose recipients this 
was 100%, 68%, and 67% in empagliflozin (25 mg), 
canagliflozin (300 mg), and dapagliflozin (10 mg), respectively 
[12,17,18]. While the serious side effects did not happen with 
any dosages of empagliflozin in a trial [17], in dapagliflozin 
recipients, it was more frequent with the low dose (5mg, 7%) 
than the large dose (10mg, 2.6%) [18]. The serious side effects 
were found in 12.5% of T1DM patients using 400 mg 
sotagliflozin in a trial [19]. In T1DM patients, the proportion of 
hypoglycemic side effects was dose irrespectively high in all 
canagliflozin users (98-99%) [12], but in empagliflozin users, it 
varied dose-wise (2.5mg: 84%, 10mg: 68%, 25mg: 94%) [17]. 
     Given the safety concerns leading to non-approval of these 
drugs' use in T1DM patients by the US FDA and agglomeration 
of available clinical trials that tested their safety profile, it is 
imperative to synthesize novel evidence in this regard. 
Interestingly, the existing review articles have primarily 
compared the safety profile of SGLTis with the placebo [20–
23]. Although review attempts have been made to study the 
safety profile between large and low doses of specific SGLT2 
inhibitors like empagliflozin and dapagliflozin [24,25], none 
have contrasted it across multiple SGLTis to synthesize 
summative evidence in this context. Therefore, to explore this 
under-reviewed area, we propose this systematic review and 
meta-analysis protocol. 
 
Methods   
The proposed review’s inclusion criteria will be the following: 
a. Study design: Parallel-arm (any number of arms) randomized 
controlled trials. b. Participants: Adult (18 years or older) 
insulin-treated T1DM patients irrespective of their gender. The 
diagnosis of T1DM will be accepted as per the trialists. c. 
Intervention arm: The intervention groups should receive a 
mega-dose of dapagliflozin (10 mg), empagliflozin (25 mg), 
canagliflozin (300 mg), or sotagliflozin (400 mg) every day. 
The determination of these mega doses was based on the 
maximum dose in which they were tested in T1DM patients in 
different clinical trials [12,17–19]. When the proposed review 
commences, if trials on any other SGLTis are found (besides 
those mentioned-above like ertugliflozin) matching the 
inclusion criteria, we will include those too in the same manner. 
d. Comparator arm: The comparator group/s should receive the 
same drugs as the intervention arm, however, at a lower dose. e. 
Outcome: Trials reporting side effects of SGLTis will be 
included. The definitions of these outcomes will be accepted as 
per the trialists.  
The exclusion criteria will incorporate the following: a. Trial 
population diagnosed with type-2 diabetes, gestational diabetes, 
or maturity-onset diabetes of young. b. Studies of other designs 
like crossover trials or quasi-experimental studies. 
     The proposed review protocol is registered in Prospective 
Register of Systematic Reviews (PROSPERO) (registration no. 
CRD42019146578) [26]. This protocol follows the PRISMA-P 
checklist [27]. 
 
Search for eligible trials  
Next, the eligible trials’ titles and abstracts will be searched in 
various electronic databases (PubMed, Embase, and Scopus). 
The search will not be limited to any date, but it will be 
restricted to the English language only. 
     The search strategy to be used in the PubMed database is 
described here.  Following search terms will be used: ‘safety’ 
OR ‘tolerance’ OR ‘adverse event’ OR ‘side effect’ OR ‘side-
effect’ and ‘canagliflozin’ OR ‘dapagliflozin’ OR 
‘empagliflozin’ OR ‘sotagliflozin’ OR ‘sodium-glucose 
cotransporter’ OR cotransporter* OR sglt* and ‘type-1’ OR 
‘type 1’ and ‘diabetes.’ The search will be narrowed down to 
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clinical trials by using the filter ‘Randomized Controlled Trial’ 
and ‘Clinical Trial.’ For other databases without such filters, 
instead, the following search terms will be used - ‘trial’ OR 
‘randomized’ OR ‘randomized’ OR ‘controlled.’  Additionally, 
eligible trials will also be searched in the references of papers 
included in the proposed review. 
 
Selection of eligible trials  
The database search results will be uploaded to the Rayyan [28] 
systematic reviews software. Then, after excluding the 
duplicates, the titles and abstracts of papers will be read to find 
trials matching the above-mentioned eligibility criteria. A paper 
will be read in entirety if it seems to be eligible for inclusion in 
this review or when a decision of inclusion or exclusion cannot 
be made by reading the excerpts alone. The list of publications 
excluded after reading full-text will be retained with their 
reasons for elimination. The entire study selection process will 
adhere to the Prisma 2009 flow diagram [29]. 
     When multiple trials source data from the same study 
population, one that counted the overall side effects (cause 
irrespective) based on the maximum number of side effects will 
be reviewed. If these latter are identical between trials, one with 
the longest follow-up time for adverse effects will be included 
in the review. 
 
Data extraction 
From the recruited trials, information about its details, 
participant characteristics, interventions compared, and 
outcomes of interest will be extracted. In trial details, its 
registration number, randomization method, blinding, duration, 
number of intervention arms, site (single centered or 
multicentric), participant consent, ethical clearance, country 
(where conducted), and funding information will be collected. 
The following participant characteristics will be gathered - 
diagnosis, their number in each intervention arm, mean age, the 
average duration for which they have been diagnosed with 
T1DM, and their number for whom the outcome data of interest 
is not available. Concerning intervention information, the 
dosage and treatment regimen of each of the intervention arm 
will be collected. Finally, for the outcomes of interest, the 
number of participants experiencing it after taking at least one 
dose of the tested intervention will be extracted from each of 
the intervention groups.  
 
Risk of bias assessment 
For each trial, using the Cochrane tool, the risk of selection 
bias, performance bias, detection bias, attrition bias, reporting 
bias, and miscellaneous bias will be evaluated and categorized 
as low risk, high risk, or unclear (if it does not meet the low or 
high-risk categorization) [30]. 
     The selection bias will be assessed by the random sequence 
generation method used to allocate interventions to the 
participants and the means used to conceal this allocation from 
the participants [30]. The performance bias will be based on the 
adequate blinding of study participants and personnel [30]. 
Depending on the blinding mechanism of the outcome 
assessors, the detection bias will be judged [30]. Based on the 
reasons and balance in missing outcome data between treatment 
arms, attrition bias will be evaluated [30,31]. By comparing the 
variation in a trial's reported findings from its protocol or pre-
stated plans, the reporting bias will be assessed [30]. 
 
Author’s roles 
The review authors will independently do the literature search, 
data abstraction, and risk of bias assessment, and resolve 
conflict in opinions by discourse. If such disagreements sustain, 
a third-party opinion will be sought. 
 
Meta-analysis 
For binomial outcomes, risk ratios will be estimated. Whereas, 
for continuous outcomes, meta-analytic standardized or 
weighted mean difference estimation will use the endpoint 
means and its standard deviations (SD). If this endpoint SD for 
an outcome is unavailable in a trial, it will be substituted by the 
SD of the baseline mean of that outcome, and the meta-analysis 
will be performed using the mean changes and its SD changes 
from the baseline (using correlation coefficient 0.5). In trials 
with more than one intervention arms testing the low dosages, 
the respective outcome data will be combined across these 
treatment arms. The summary estimate from meta-analysis will 
be analyzed using either a random-effect model (Der Simonian 
and Laird method) or a fixed-effect model (inverse variance 
method). This model choice will depend on the clinical 
heterogeneity of the trials like trial settings, study design, 
participant characteristics, etc. and not the pre-determined 
statistical inconsistency. If the reviewed trials are clinically 
heterogeneous, a random-effect model will be used or vice-
versa. 
     A trial will be excluded from the meta-analysis if the 
outcome does not happen in both of the contrasting treatment 
arms. However, for dichotomous outcomes, when it happens in 
either of these arms, 0.5 will be added to each cell of the 2x2 
table, and the trial will be incorporated in the meta-analysis. 
For summary estimates of meta-analysis, a statistical 
significance will be determined at a P <0.05 (and 95% 
confidence interval). The trials with a high risk of bias will not 
be included in the meta-analysis. Any outcome for which a 
quantitative juxtaposition is not possible, a narrative reporting 
will ensue. 
 
Heterogeneity and publication bias 
Using the I2 and Chi2 statistics, the statistical inconsistency 
among the trials will be determined. At the I2 statistics values of 
0-40%, 30-60%, 50-90%, and 75-100%, the heterogeneity will 
be categorized as less, moderate, substantial, and considerable, 
respectively [30]. At a P <0.1, the statistical significance of the 
Chi2 statistics will be estimated [30].  
     If considerable statistical heterogeneity is detected in a meta-
analysis of at least 10 trials, a subgroup analysis will be done. It 
will be done between the trials testing SGLT2 inhibitors and the 
dual SGLT2/1 inhibitor, between the trials in which the 
participants’ estimated glomerular filtration rate (GFR) was less 
than 60 mL/min/1.73 m2 and more than 60 mL/min/1.73 m2, 
and based on missing outcome data. Publication bias will be 
assessed using funnel plots. Additionally, an Egger’s test will 
be used when at least ten trials are available for meta-analysis.   
Additional analysis 
The following types of sensitivity analysis will be done by 
repeating the meta-analysis- a. By using a different meta-
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analysis model (fixed effect or random effect) then that was 
used during the preliminary analysis. b. By dropping one trial 
every time. c. By eliminating trials shorter than two weeks 
duration. d. By excluding trials that included trial population 
with GFR less than 60 mL/min/1.73 m2. e. If the mean changes 
and their SDs are used for any meta-analysis, the analysis will 
be iterated using a different correlation coefficient to determine 
the SD change (e.g., 0.8). 
     In the subgroup and sensitivity analysis proposed above, the 
rationale for using the benchmark of an optimum GFR (60 
mL/min/1.73 m2) is that SGLT2 inhibitors is not recommended 
in T2DM patients with very low GFR [2]. Therefore, the notion 
is to see if such GFR plays any role in T1DM patients too. 
Finally, for the dichotomous outcomes with statistically 
significant meta-analytic results, imputation case analysis (ICA) 
will be done to test the robustness of the preliminary analysis 
[32]. Assuming the event's occurrence and non-occurrence in all 
of the missing participants, the ICA-1 and ICA-0 analyses will 
be conducted, respectively. Moreover, the best- and worst-case 
scenario will be assessed along with the Gamble-Hollis analysis 
[33]. Statistically significant outcomes' will be graded for the 
quality of evidence using the Grades of Recommendation, 
Assessment, Development, and Evaluation (GRADE) Working 
Group’s GRADE approach [34]. All analyses will be performed 
in Stata statistical software version 16 (StataCorp, College 
Station, Texas, USA). 
 
Discussion 
The chief implication of the prospective systematic review is 
that it will be one of the preliminary attempts to synthesize 
evidence in this context. It will perhaps help physicians, pharma 
companies, and relevant health authorities to understand how 
the side effects of SGLTis vary between different doses. 
Additionally, the proposed study's findings will help in 
comparing the results with similar research conducted on 
T2DM patients. 
     Regarding the strengths, evidence generated from the 
proposed review is likely to be rigorous since it will be based 
on randomized controlled trials (the highest level of 
epidemiological evidence). Its comprehensiveness is likely to be 
ensured due to not limiting the database search to any date 
range. Furthermore, the range of proposed sensitivity and 
imputation analysis will provide an idea of the robustness of the 
evidence generated from the review.   
     Despite these strengths, the suggested review is likely to 
have few weaknesses. At the review level, the inclusion of 
randomized controlled trials only limits its scope of reviewing 
studies of other designs like crossover trials or quasi-
experimental studies, or good quality observational studies. 
Besides, limiting the database search to the English language 
literature only narrows down the scope of reviewing trials 
published (if any) in other languages. Lastly, since the diagnosis 
of T1DM and outcome definitions will be accepted as per the 
trialists, if the trials are extremely heterogenous in this context, 
the synthesized evidence may be at risk of bias. 
 
Conclusion  
The proposed review will compare the safety profile between 
high and low doses of SGLTis in insulin-treated T1DM 
patients.   
Abbreviation 
 GFR: Glomerular filtration rate; GRADE: Grades of Recommendation, 
Assessment, Development, and Evaluation; ICA: Imputation case 
analysis; PROSPERO: Prospective Register of Systematic Reviews; 
SGLTis: Sodium-glucose co-transport inhibitors; SGLT1: Sodium-
glucose transporter 1; SGLT2: Sodium-glucose transporter 2; SD: 
Standard deviations ; T1DM: Type 1 diabetes mellitus ; T2DM: Type 2 
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